FDA product approval
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Research compound · supplement · checked 2026-10-09
TUDCA (Tauroursodeoxycholic Acid)
TUDCA (Tauroursodeoxycholic Acid) is listed here as a supplement. Taurine-conjugated bile acid investigated in disease-specific settings. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use TUDCA (Tauroursodeoxycholic Acid) or how much to take.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- not established
- Compounding
- not established
- Research
- investigational
- Sport
- unknown
What is TUDCA (Tauroursodeoxycholic Acid)?
Other names in the library: tauroursodeoxycholic acid, TUDCA - 250mg, TUDCA - 500mg, TUDCA. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 250 mg, 500 mg. A seller title is a listing. It does not prove the vial matches a paper.
Taurine-conjugated bile acid investigated in disease-specific settings.
Regulatory status, dated 2026-10-09
Compounding
not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.
Research
investigational. 34 ALS patients receiving riluzole in an early proof-of-principle randomized trial.
Sport
unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.
What the cited papers actually measured
We mark the cited papers as C for 34 ALS patients receiving riluzole in an early proof-of-principle randomized trial. and An early small ALS study reported benefit, but the later 336-participant Phase 3 trial did not meet its primary or secondary endpoints.. The larger study did not confirm the early signal. Recruitment and attrition during COVID limited precision. These disease-specific trials do not establish general liver or wellness benefits. An early study examined functional decline. A small early disease-specific study is not proof of liver detoxification or a confirmed current ALS treatment. Later trial outcomes must be checked before any treatment conclusion. The Phase 3 TUDCA-ALS trial did not show significant benefit on its primary functional endpoint or secondary survival and biomarker endpoints. Top-line consortium report; pandemic recruitment and attrition limited precision. EU-funded research, not a commercial-product equivalence study. Risks on the record: Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
We mark the cited papers as C. That is our label for how strong those papers are. It does not say the compound works.
human-trial
An early study examined functional decline.
34 ALS patients receiving riluzole in an early proof-of-principle randomized trial. A small early disease-specific study is not proof of liver detoxification or a confirmed current ALS treatment. Later trial outcomes must be checked before any treatment conclusion.
human-trial
The Phase 3 TUDCA-ALS trial did not show significant benefit on its primary functional endpoint or secondary survival and biomarker endpoints.
336 randomized participants with ALS across 25 European sites; consortium announcement March 27, 2024. Top-line consortium report; pandemic recruitment and attrition limited precision. EU-funded research, not a commercial-product equivalence study.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.
Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.
U-100 math for listed TUDCA (Tauroursodeoxycholic Acid) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 250 mg | 2500 | 1250 | 833.3 |
| 500 mg | 5000 | 2500 | 1666.7 |
Risks and mix-ups already on the record
- Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
- No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
- No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.
People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.
Sources
- TUDCA primary study · PMID 25664595 · checked 2026-10-09
- TUDCA-ALS consortium: Phase 3 top-line results (2024) · checked 2026-10-09
Questions people ask
Is TUDCA (Tauroursodeoxycholic Acid) FDA-approved?
not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.
Does PepBear pick an amount of TUDCA (Tauroursodeoxycholic Acid)?
The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.
Related cards
Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.